Sugi Predict

Sugi Predict / Targets / TIE1

TIE1

Tyrosine-protein kinase receptor Tie-1 · P35590 · TIE1 on Sugi Atlas →

14,993 patent compounds predicted against TIE1, 13,182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL431504 SCHEMBL431504 0.71 3/20
SCHEMBL431966 SCHEMBL431966 0.71 3/20
SCHEMBL431792 SCHEMBL431792 0.69 3/20
SCHEMBL447272 SCHEMBL447272 0.69 3/20
SCHEMBL433297 SCHEMBL433297 0.69 3/20
SCHEMBL448010 SCHEMBL448010 0.69 3/20
SCHEMBL431623 SCHEMBL431623 0.68 3/20
SCHEMBL431737 SCHEMBL431737 0.68 3/20
SCHEMBL430939 SCHEMBL430939 0.67 3/20
SCHEMBL430952 SCHEMBL430952 0.67 3/20
SCHEMBL431798 SCHEMBL431798 0.67 3/20
SCHEMBL446188 SCHEMBL446188 0.67 3/20
SCHEMBL446550 SCHEMBL446550 0.67 3/20
SCHEMBL446757 SCHEMBL446757 0.67 3/20
SCHEMBL448686 SCHEMBL448686 0.67 3/20
SCHEMBL448792 SCHEMBL448792 0.67 3/20
SCHEMBL431042 SCHEMBL431042 0.66 3/20
SCHEMBL447836 SCHEMBL447836 0.66 3/20
SCHEMBL448311 SCHEMBL448311 0.66 3/20
SCHEMBL431711 SCHEMBL431711 0.65 3/20

Clinical trials — most relevant to TIE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study PHASE2/PHASE3UNKNOWN
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer PHASE2COMPLETED
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. PHASE2RECRUITING
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression PHASE2COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib PHASE1/PHASE2COMPLETED
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy PHASE2UNKNOWN
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Treatment for Patients With Metastatic Thyroid Cancer PHASE2COMPLETED
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk PHASE2RECRUITING
Anlotinib in Metastatic HER2 Negative Breast Cancer PHASE2COMPLETED
Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI PHASE2COMPLETED
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC PHASE1/PHASE2UNKNOWN
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma PHASE2COMPLETED
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer PHASE2UNKNOWN
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration PHASE1COMPLETED
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors PHASE1WITHDRAWN
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) PHASE1ACTIVE_NOT_RECRUITING
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function PHASE1COMPLETED
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib nanCOMPLETED
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial nanUNKNOWN
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TIE1 binder may also engage these)

ProteinNameSimilarity
Q06805 — 1.000 Q06805 →
Q06806 — 1.000 Q06806 →
EPHB4 Ephrin type-B receptor 4 0.995 landscape →
O73791 — 0.993 O73791 →
P0C0K6 — 0.993 P0C0K6 →
P0C0K7 — 0.992 P0C0K7 →
Q8BYG9 — 0.992 Q8BYG9 →
Q92729 — 0.992 Q92729 →
Q13308 — 0.992 Q13308 →
P35546 — 0.992 P35546 →
O09127 — 0.992 O09127 →
INSRR Insulin receptor-related protein 0.991 landscape →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.991 landscape →
Q00495 — 0.990 Q00495 →
P13369 — 0.989 P13369 →
Q9WTL4 — 0.989 Q9WTL4 →
P54754 — 0.989 P54754 →
Q8K1S3 — 0.989 Q8K1S3 →
Q9EQS9 — 0.989 Q9EQS9 →
Q60750 — 0.988 Q60750 →
P54761 — 0.988 P54761 →
O08644 — 0.988 O08644 →
B4HY03 — 0.988 B4HY03 →
Q1KL86 — 0.988 Q1KL86 →
Q2EY13 — 0.988 Q2EY13 →
EPHB3 Ephrin type-B receptor 3 0.988 landscape →
P14617 — 0.988 P14617 →
P51840 — 0.988 P51840 →
Q9NR61 — 0.988 Q9NR61 →
Q8TDY8 — 0.988 Q8TDY8 →